BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 30371316)

  • 1. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
    J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
    Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
    J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
    Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
    Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
    J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory measurement of the direct oral anticoagulants.
    Dale BJ; Chan NC; Eikelboom JW
    Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
    Du S; Harenberg J; Krämer S; Krämer R; Wehling M; Weiss C
    Ther Drug Monit; 2015 Jun; 37(3):375-80. PubMed ID: 25525760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.
    Mahamad S; Chaudhry H; Nisenbaum R; McFarlan A; Rizoli S; Ackery A; Sholzberg M
    J Thromb Thrombolysis; 2019 Feb; 47(2):272-279. PubMed ID: 30506352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.
    Liu Z; Zhang H; Xie Q; Mu G; Zhou S; Wang Z; Wang Z; Jiang J; Xiang Q; Cui Y
    Clin Ther; 2020 Oct; 42(10):2066-2081.e9. PubMed ID: 32900534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of direct oral anticoagulants on thrombin generation on Ceveron TGA.
    Pfrepper C; Behrendt LC; Bönigk H; Siegemund T; Metze M; Franke D; Petros S; Siegemund A
    Int J Lab Hematol; 2022 Feb; 44(1):193-201. PubMed ID: 34585540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
    Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
    Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
    Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
    Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
    J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring Direct Oral Anticoagulants.
    Gosselin RC; Douxfils J
    Methods Mol Biol; 2017; 1646():217-225. PubMed ID: 28804832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
    Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients.
    Bluecher A; Meyer Dos Santos S; Ferreirós N; Labocha S; Meyer Dos Santos IM; Picard-Willems B; Harder S; Singer OC
    Thromb Haemost; 2017 Feb; 117(3):519-528. PubMed ID: 28124061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
    von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
    Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
    Cuker A; Siegal DM; Crowther MA; Garcia DA
    J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.